OUTLOOK THERAPEUTICS INC

Outlook Therapeutics is preparing for the U.S. commercial launch of LYTENAVA after the FDA approved it as the only FDA-approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration. The company estimates the U.S. anti-VEGF retina market at about $8.5 billion annually and targets more than $500 million in peak annual LYTENAVA sales by 2030, with first-year post-launch revenue projected at $50 million to $75 million and pricing expected below $500 per vial. It plans to hire roughly 50 field personnel, including about 30 customer-facing commercial employees and 20 field reimbursement staff, and expects to submit a permanent HCPCS code application by the end of the third quarter. The company reported an adjusted quarterly net loss of $10.9 million and had $11.2 million in cash as of June 30, with a subsequent $55 million stock-and-warrant offering expected to provide about $51.1 million in net proceeds to fund the launch and working capital.

Outlook Therapeutics has received U.S. Food and Drug Administration approval for LYTENAVA, making it the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration. The approval provides retina specialists and patients with a purpose-built intravitreal therapy backed by rigorous clinical evidence, validated manufacturing, and ongoing regulatory oversight, replacing reliance on repackaged intravenous formulations. The company anticipates 12 years of market exclusivity under the Biologics Price Competition and Innovation Act and is now executing a commercial launch into the approximately $8.5 billion U.S. retina market, with product availability expected before year-end. Outlook Therapeutics believes LYTENAVA can become the new FDA-approved standard for bevacizumab therapy in wet AMD, where bevacizumab already accounts for the majority of first-line anti-VEGF treatment.

Shares of Outlook Therapeutics rallied 35.3% on Tuesday after the FDA accepted the resubmitted Biologics License Application for its investigational wet AMD treatment ONS-5010, also known as Lytenava. The agency classified the filing as a Class 1 resubmission, setting a decision date of July 29, 2026, and management said the acceptance marks the final stage of the regulatory review process with discussions now focused on product labeling. The acceptance follows a favorable outcome in May 2026 from a Formal Dispute Resolution process in which the FDA concluded that substantial evidence of effectiveness had been established based on the NORSE TWO study together with confirmatory evidence from NORSE EIGHT and additional datasets, effectively overturning the key deficiency cited in three prior complete response letters. If approved, Lytenava would become the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD, offering standardized manufacturing and FDA-approved labeling. The drug is already approved in the EU and the United Kingdom, where it has been commercially launched in several markets.